• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

Revance to introduce TEOXANE RHA® fillers in the U.S.


The distribution agreement between Revance and Swiss HA-based dermal filler and cosmeceutical manufacturing company, TEOXANE SA, may position Revance as a leader in the U.S. facial injectable market.

Revance Therapeutics, a biotechnology company specializing in neuromodulator innovations, recently announced a U.S. distribution agreement with Swiss hyaluronic acid (HA)-based dermal filler manufacturing company, TEOXANE SA.

The partnership gives Revance immediate and exclusive access to the company’s range of Resilient HA (RHA) fillers in the United States, with TEOXANE gaining 2.5 million shares of Revance common stock in return, according to the press release.

Along with TEOXANE’s Food and Drug Administration (FDA)-approved RHA 2, RHA 3 and RHA 4 products that include lidocaine, it also includes a fourth product, RHA 1, which is currently in clinical trials, with anticipated FDA approval in 2021.

TEOXANE says their patented RHA crosslinking method preserves the HA network for correction of moderate to severe facial wrinkles and folds and optimizes strength, stretch and tissue integration.

“We are eager to introduce U.S. physicians and consumers to our exciting, highly differentiated RHA range of dermal fillers,” says Valerie Taupin, founder and chief executive officer of TEOXANE.

Revance believes that adding the RHA line of products to its own neuromodulator, DaxibotulinumtoxinA (DAXI), which combines a “proprietary stabilizing peptide excipient with a highly purified botulinum toxin without human or animal-based components,” will position them as a leader in the $2 billion U.S. facial injectable market.


Phase 3 trials for DAXI in glabellar line treatment is complete and U.S. regulatory approval is anticipated in 2020. The company is also evaluating the use of DAXI in forehead lines and crow’s feet, as well as for therapeutic use in cervical dystonia, adult upper limb spasticity and plantar fasciitis. There are also plans to study DAXI for migraine use.

The release indicates this is an ongoing collaboration between the two companies and a right of first negotiation for access to TEOXANE’s novel cosmeceutical line, which also incorporates RHA technology.

“This is a transformational deal for Revance, giving us access to the fast-growing, billion-dollar U.S. dermal filler market, with a line of highly differentiated fillers that are complementary to our first and only, long-lasting neuromodulator,” says Mark Foley, president and chief executive Officer of Revance. “This deal provides commercial synergies, organizational leverage and fast-tracks the build-out of our sales organization. It also creates a broad foundation from which to launch DAXI upon anticipated approval later this year.”

Revance is targeting the second quarter of 2020 to introduce the line of TEOXANE RHA fillers in the U.S., according to the release.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.